Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
Architects: Biotechnology_CAR-T (Chimeric Antigen Receptors-T Cell), T Cell Engager (TCE) & T-Cell Research
Dendreon (NASDAQ: DNDN), #10 (Biotech-Patent Board-2007),

Organization & Developments: Dendreon

Parents

2011: An Open Letter to Dendreon’s Chairman (2011)
Dendreon is a biotechnology company targeting cancer through the discovery, development, commercialization and manufacturing of novel therapeutics.
Dendreon:New Product R&D and Business Developments
Dendreon's Infectious Influence on Biotechs (2011)
Dendreon’s sipuleucel-T (Provenge)
Immune-boosting therapy for prostate cancer
The approval of the first cancer therapeutic vaccine from Dendreon in prostate cancer establishes the concept that immunotherapy is a conceptually achievable and clinically useful approach for treating cancer.
The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response in a variety of tumor types.